In recent years, molecularly targeted agents, epidermal growth factor receptor tyrosine kinase receptor inhibitors (EGFR-TKI), including osimertinib and erlotinib, have exhibited good antitumor effects in both NSCLC (3–5). Here, EGFR is linked to non-small cell lung carcinoma.